Pre-Operative Combination of Normal BMI with Elevated YKL-40 and Leptin but Lower Adiponectin Level Is Linked to a Higher Risk of Breast Cancer Relapse: A Report of Four-Year Follow-Up Study

• Published in: Journal of clinical medicine Vol. 9; no. 6; p. 1742
• Main Authors: Bielawski, Kornel, Rhone, Piotr, Bulsa, Marek, Ruszkowska-Ciastek, Barbara
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 04-06-2020; MDPI
• Subjects: Anticoagulants; Biomarkers; Body mass index; Breast cancer; Cancer therapies; Cell growth; Clinical medicine; Cytokines; Disease; Epidermal growth factor; Females; Inflammation; Laboratories; Mammography; Medical prognosis; Menstruation; Metastasis; Obesity; Patients; Plasma; Proteins; Surgery; Survival analysis; Tumor necrosis factor-TNF; Tumors; United Kingdom > UK
• ISSN: 2077-0383; 2077-0383
• DOI: 10.3390/jcm9061742

Adipokines are powerful agents involved in the development of obesity-dependent cancers. This prospective study aimed to investigate the association between pre-treatment body mass index (BMI) and serum YKL-40, leptin, and adiponectin concentrations as well as the plasma activity of tissue factor (TF) and the future prognosis of early, non-metastatic breast cancer (BrC) subjects. The serum levels of YKL-40, leptin, and adiponectin as well as plasma TF activity, anthropometric parameters, and clinicopathological parameters were analysed in 81 treatment-naïve females with invasive BrC. The predictive value of YKL-40, BMI, leptin, adiponectin, and TF was determined with a 95% confidence interval (CI). Kaplan–Meier plots and log-rank and F Cox tests were used to determine the clinical outcomes of progression-free survival (PFS). The median follow-up duration was 44 months with complete follow-up for the first event. Follow-up revealed a significantly higher incidence of disease relapse in BrC patients with a high baseline concentration of YKL-40 (22.22%) and TF activity (21.43%). Body mass index was an independent predictor of survival, with women who were overweight/obese being less prone to relapse (hazard ratio (HR): 0.75; 95% CI: 0.59 to 0.95). The recurrence rates for normal-weight BrC cases was 21.05% versus 7.14% for their overweight counterparts. The receiver operating characteristic analysis showed the strong ability of the analysed biomarkers to predict disease progression, with an area under the receiver operating characteristics (ROC) curve of 0.84 (95% CI, 0.823 to 0.931). In a prospective cohort of invasive BrC patients, overweight/obesity was associated with improved future outcomes. The combination of a normal BMI with high leptin and low adiponectin levels and high TF activity was associated with an increased risk of recurrence and decreased survival.